Irritable Bowel Syndrome

Bifidobacterium longum 35624TM reduces IBS symptom severity in children and adolescents, according to a study presented at NASPGHAN 2024.

NASPGHAN 2024 data suggests children and adolescents with a history of COVID-19 were twice as likely to develop IBS during the follow-up period.

This month in review spotlights HCPLive’s coverage of the ACG 2024 meeting, GI pipeline updates, and other news and research from October.

A new study revealed patients with genetic variation of hCAZyme enzymes were more likely to reach success with low-carb diets to relieve IBS symptoms than those without.

Brain-gut behavioral treatments, such as CBT and hypnotherapy, may alleviate abdominal pain in IBS, though no single therapy proves superior to others.

Patients with greater HADS-D scores were less likely to achieve symptomatic response or remission with a 2-step dietary intervention for IBS.

Adherence to an adapted low FODMAP diet and its impact on IBS symptoms were not affected based on the presence of fibromyalgia.

Linaclotide was safe and effective for patients with chronic constipation and IBS with constipation who switched after non-response to magnesium oxide.

In focus groups, patients indicated symptom bothersomeness and life interference should be included in clinical evaluation for disorders of gut-brain interaction.

Patients taking GLP-1 RAs were more likely to show food retention and inadequate bowel preparation, even when the medications were held before the procedure.

This month in review spotlights recent GI pipeline news, new research about IBS and other gastroenterological conditions, and coverage from the 2024 GHAPP conference.

Subgroup analyses revealed FMT delivered through endoscopy, nasojejunal tube, and rectal enema had a greater impact on clinical response, symptom improvement, and quality of life.

Oral vitamin D improves vitamin D status and quality of life in IBS patients but does not significantly reduce symptom severity, a new study suggests.

A new study finds causal links between schizophrenia and MDD on IBS, highlighting the need for integrated care addressing both psychiatric and gastrointestinal symptoms.

Findings highlight disease burden and ongoing unmet needs in patients with IBS-C and IBS-D, suggesting the benefit of prescription medications on rates of satisfaction and symptom control.

Patients with positive endoscopic findings for upper gastrointestinal mucosal damage had a greater risk of developing Parkinson disease compared to those without mucosal damage.

A new study discovers patients with IBD who respond well to high-dose thiamine treatment have an abundance of faecalibacterium prausnitzii.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

The May 2024 gastroenterology month in review spotlights top research from Digestive Disease Week 2024 and the FDA approval of ColoSense.

In recognition of World IBS Day, we spoke with Jeffrey Roberts about what led him to found the holiday in 2019 and took a closer look at the continued marginalization of the condition.

The post-hoc analysis found tenapanor significantly improved weekly scores for abdominal pain, discomfort, and bloating, as measured by the Abdominal Score.

Test your knowledge of the AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases with this clinical quiz!

Our February 2024 month in review highlights EoE pipeline news, new FMT guidelines, and research about endoscopic inflammation and disease activity in IBD.

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.

Adhering to a greater number of healthy lifestyle behaviors was linked to a decreased risk of incident IBS, suggesting lifestyle modifications may help prevent its onset.

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.

Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.